Signal category
Track how regulatory decisions alter competitive positioning, launch timelines, and investor expectations across therapeutic areas.
FDA approvals, label changes, advisory committee outcomes, and global regulatory shifts that reshape asset and portfolio strategy.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.
Company
AbbVie
Asset
Quinacrine Hydrochloride
Indication
Dermatology / Autoimmune Disease
Status
Approved
Signal Score
8.2
Quinacrine is included on the FDA 503B list for compounding, indicating a clinical need for its use in treating cutaneous lupus erythematosus.
Pfizer
Asset
Keytruda
Indication
Oncology / Drug Development
Status
Under Review
Signal Score
8.2
The FDA has issued draft guidance to minimize unnecessary animal testing in the development of cancer drugs.
INQOVI
Asset
Taiho Oncology
Indication
Oncology / Antineoplastic
Status
Approved
Signal Score
8.4
The FDA has approved a supplemental application for INQOVI, which contains the active ingredients cedazuridine and decitabine.
Company
Immunocore
Asset
uveal melanoma
Indication
Oncology / Immune-Mobilizing T-cell Receptors
Status
Approved
Signal Score
9.6
Tebentafusp (IMCgp100) significantly improved overall survival in HLA-A*02:01-positive advanced uveal melanoma, establishing it as a first-line treatment.
Merck
Asset
ENFLONSIA
Indication
Infectious Disease / Respiratory Syncytial Virus (RSV)
Status
Approved
Signal Score
9.6
The European Commission has approved ENFLONSIA (clesrovimab) as the first RSV preventive option for infants in the EU.
Company
Merck
Asset
KEYTRUDA
Indication
Oncology / Bladder Cancer
Status
Approved
Signal Score
8.4
The FDA has granted priority review for KEYTRUDA and KEYTRUDA QLEX in combination with Padcev for muscle-invasive bladder cancer.
Company
Merck
Asset
IDVYNSO
Indication
Infectious Disease / HIV
Status
Approved
Signal Score
8.4
Merck's IDVYNSO, a two-drug regimen, has been approved by the FDA for adults with virologically suppressed HIV-1.
Company
Roche
Asset
Gazyva
Indication
Immunology / Systemic Lupus Erythematosus
Status
Approved
Signal Score
9.6
The FDA has accepted Roche's sBLA for Gazyva/Gazyvaro, based on phase III ALLEGORY data showing significant efficacy in SLE.
Signal Score
8.4
Antibody-drug conjugates (ADCs) have shown significant clinical benefits in advanced phase trials for various cancers, with over a dozen receiving FDA approval.
Company
Merck
Asset
IDVYNSO
Indication
Infectious Disease / HIV-1
Status
Approved
Signal Score
8.4
Merck has received U.S. FDA approval for IDVYNSO, a once-daily oral treatment for certain adults with virologically suppressed HIV-1.
Company
Amgen
Asset
Bizengri
Indication
Oncology / NRG1 Fusion-Positive Cholangiocarcinoma
Status
Approved
Signal Score
8.4
The FDA has approved Bizengri (zenocutuzumab-zbco) for the treatment of NRG1 fusion-positive cholangiocarcinoma.
Company
Type 1 Diabetes
Asset
Endocrinology
Indication
Endocrinology / Type 1 Diabetes
Status
Approved
Signal Score
8.4
The FDA granted accelerated approval for Tzield (teplizumab) to delay insulin production decline in pediatric patients with Stage 3 T1D.
Company
AstraZeneca
Asset
HR-positive breast cancer
Indication
Oncology / Breast Cancer
Status
Approved
Signal Score
8.4
The FDA's ODAC did not reach a majority vote in favor of camizestrant's benefit-risk profile for advanced HR-positive breast cancer.
Company
Eli Lilly
Asset
Dermatology
Indication
Dermatology / Atopic Dermatitis
Status
Approved
Signal Score
8.4
Lilly's EBGLYSS® (lebrikizumab-lbkz) is now approved for a maintenance dose every eight weeks, requiring only six injections per year.
Company
Merck
Asset
KEYTRUDA
Indication
Oncology / KRAS G12C Inhibitor
Status
Approved
Signal Score
8.4
Calderasib (MK-1084) received Breakthrough Therapy designation for first-line treatment of KRAS G12C-mutant NSCLC.
Company
AstraZeneca
Asset
Saphnelo
Indication
Immunology / Systemic Lupus Erythematosus
Status
Approved
Signal Score
8.4
AstraZeneca's Saphnelo has received FDA approval for self-administration via a new autoinjector, enhancing patient convenience.
Company
Roche
Asset
individuals with cognitive decline
Indication
Neurology / Alzheimer's Disease
Status
Approved
Signal Score
8.4
Roche has received CE Mark approval for Elecsys® pTau217, the first blood test designed to detect Alzheimer's disease pathology.
Company
Roche
Asset
individuals with cognitive decline
Indication
Neurology / Alzheimer's Disease
Status
Approved
Signal Score
9.6
Roche has received CE Mark approval for Elecsys® pTau217, the first blood test for Alzheimer's disease pathology, enabling faster diagnosis.
Company
Pfizer
Asset
HYMPAVZI
Indication
Hematology / Hemophilia A/B
Status
Approved
Signal Score
8.4
The European Commission has approved HYMPAVZI for treating hemophilia A or B in patients 12 years and older with inhibitors, based on Phase 3 data showing significant bleed reduction.
Company
AstraZeneca
Asset
hormone receptor-positive breast cancer
Indication
Oncology / Hormone Receptor-positive Breast Cancer
Status
Approved
Signal Score
8.4
The FDA has extended the PDUFA date for camizestrant to allow for additional data review related to its NDA.
Company
AstraZeneca
Asset
Truqap
Indication
Oncology / Prostate Cancer
Status
Approved
Signal Score
8.4
Truqap, a first-in-class AKT inhibitor, has been approved in the US for treating PTEN-deficient metastatic hormone-sensitive prostate cancer.
Company
AstraZeneca
Asset
Imfinzi
Indication
Oncology / Immunotherapy
Status
Approved
Signal Score
8.4
Imfinzi has been approved in the US as the first immunotherapy combination for BCG-naïve, high-risk non-muscle-invasive bladder cancer, showing a 32% reduction in disease recurrence, progression, or death.
Company
AstraZeneca
Asset
Enhertu
Indication
Oncology / HER2-positive Breast Cancer
Status
Approved
Signal Score
8.4
Enhertu has received FDA approval for two new indications in HER2-positive early breast cancer, both before and after surgery.
AstraZeneca
Asset
Truqap
Indication
Oncology / Prostate Cancer
Status
Approved
Signal Score
9.6
The FDA ODAC has recommended Truqap in combination with abiraterone and ADT for PTEN-deficient metastatic hormone-sensitive prostate cancer.
Company
AstraZeneca
Asset
Datroway
Indication
Oncology / ADC
Status
Approved
Signal Score
9.6
Datroway is approved in the US as the first TROP2-directed antibody drug conjugate for 1st-line treatment of metastatic triple-negative breast cancer.
Company
AstraZeneca
Asset
Camizestrant
Indication
Oncology / ER-positive Breast Cancer
Status
Approved
Signal Score
8.4
Camizestrant, in combination with CDK4/6 inhibitor, has been recommended for approval in the EU for 1st-line advanced ER-positive breast cancer based on SERENA-6 trial results.
Company
Merck
Asset
KEYTRUDA
Indication
Oncology / Bladder Cancer
Status
Approved
Signal Score
8.4
The EU CHMP has issued a positive opinion for the combination of KEYTRUDA and Padcev as a treatment for cisplatin-ineligible muscle-invasive bladder cancer.
Company
Roche
Asset
early-stage ER-positive breast cancer
Indication
Oncology / Breast Cancer
Status
Approved
Signal Score
9.6
The FDA has accepted Roche's NDA for giredestrant, an oral SERD, under priority review based on phase III data showing a 30% reduction in invasive disease recurrence or death compared to standard therapy.
Company
Roche
Asset
early-stage ER-positive breast cancer
Indication
Oncology / Breast Cancer
Status
Approved
Signal Score
9.6
The FDA has accepted Roche's NDA for giredestrant, showing a 30% reduction in invasive disease recurrence compared to standard therapy.
Signal Score
8.4
Nanomaterial-based vaccines could enhance rotavirus vaccine efficacy, particularly in malnourished populations.
Company
Merck
Asset
KEYTRUDA
Indication
Oncology / Renal Cell Carcinoma
Status
Approved
Signal Score
8.4
The FDA has approved KEYTRUDA and KEYTRUDA QLEX in combination with WELIREG for adjuvant treatment in ccRCC patients, marking a significant advancement in therapy.
Company
Roche
Asset
AstraZeneca
Indication
Oncology / Prostate Cancer
Status
Approved
Signal Score
8.4
Roche's VENTANA PTEN (SP218) RxDx Assay is the first FDA-approved companion diagnostic for assessing PTEN protein loss in prostate cancer.
Company
Roche
Asset
Tecentriq
Indication
Oncology / Immunotherapy
Status
Approved
Signal Score
9.6
The FDA has accepted Roche's sBLA for Tecentriq plus chemotherapy in stage III dMMR/MSI-H colon cancer, with a decision expected by October 9, 2026.
Company
Roche
Asset
Tecentriq
Indication
Oncology / Immunotherapy
Status
Approved
Signal Score
8.4
The FDA has accepted Roche's sBLA for Tecentriq in combination with chemotherapy for stage III dMMR/MSI-H colon cancer, with a decision expected by October 9, 2026.
Company
Bridge Device
Asset
Opioid Use Disorder market
Indication
Addiction Medicine / Opioid Use Disorder
Status
Approved
Signal Score
8.4
The Bridge Device has received FDA clearance for the treatment of Opioid Use Disorder, emphasizing safety over efficacy.
Company
Pfizer
Asset
HYMPAVZI
Indication
Hematology / Hemophilia A/B
Status
Approved
Signal Score
8.4
The FDA has approved an expanded indication for Pfizer’s HYMPAVZI to treat hemophilia A or B in patients aged 6 and older, including those with inhibitors.
Signal Score
8.2
Torrent's ANDA for Lurasidone Hydrochloride has received an Abbreviated Approval (AP) status from the FDA.
Janssen Pharmaceuticals
Asset
SPRAVATO
Indication
Neurology / Depression
Status
Approved
Signal Score
8.2
The FDA has accepted a supplemental application for SPRAVATO, indicating ongoing development and potential label expansion.
Amivas
Asset
Artesunate
Indication
Infectious Disease / Antimalarial
Status
Approved
Signal Score
8.2
The FDA has accepted a supplemental application for Artesunate (NDA213036) submitted by Amivas.
TRAVERE
Asset
FILSPARI (SPARSENTAN)
Indication
Nephrology / SGLT2 Inhibitor
Status
Approved
Signal Score
8.2
The FDA has accepted a supplemental application for FILSPARI (SPARSENTAN) from TRAVERE.
Novitium Pharma
Asset
Pimozide
Indication
Neurology / Antipsychotic
Status
Approved
Signal Score
8.2
The FDA has granted approval for ANDA219897, a generic formulation of Pimozide submitted by Novitium Pharma.
Company
Micro Labs
Asset
Olmesartan Medoxomil
Indication
Cardiovascular / Hypertension
Status
Approved
Signal Score
8.2
The FDA has granted approval for ANDA206371, a combination of Olmesartan Medoxomil and Hydrochlorothiazide, submitted by Micro Labs.
Janssen Pharmaceuticals
Asset
Concerta
Indication
Neurology / ADHD
Status
Approved
Signal Score
8.2
The FDA has accepted a supplemental application for Concerta, a medication containing methylphenidate hydrochloride.
Company
Hospira
Asset
Lidocaine Hydrochloride
Indication
Pain Management / Local Anesthetic
Status
Approved
Signal Score
8.2
The FDA has granted Abbreviated Approval (AP) status for Lidocaine Hydrochloride 0.4% in Dextrose 5% submitted by Hospira.
Company
Hospira
Asset
Lidocaine Hydrochloride 0.4% in Dextrose 5%
Indication
Pain Management / Local Anesthetic
Status
Approved
Signal Score
8.2
The FDA has granted an approval status (AP) for ANDA083158, a supplemental application for Lidocaine Hydrochloride 0.4% in Dextrose 5% submitted by Hospira.
Sciegen Pharmaceuticals
Asset
Diltiazem Hydrochloride
Indication
Cardiovascular / Calcium Channel Blocker
Status
Approved
Signal Score
8.2
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Diltiazem Hydrochloride submitted by Sciegen Pharmaceuticals.
Company
Strides Pharma
Asset
Mycophenolate Mofetil
Indication
Immunology / Immunosuppressant
Status
Approved
Signal Score
8.2
The FDA has an active application (ANDA212634) for Mycophenolate Mofetil submitted by Strides Pharma, currently under standard review.
Sandoz
Asset
Methylprednisolone Acetate
Indication
Immunology / Corticosteroid
Status
Approved
Signal Score
8.2
The FDA has approved a supplemental application for Methylprednisolone Acetate submitted by Sandoz.
Company
Sandoz
Asset
methylprednisolone
Indication
Immunology / Corticosteroid
Status
Approved
Signal Score
8.2
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status to Sandoz for methylprednisolone.
Company
Glenmark Pharmaceuticals
Asset
Lamotrigine
Indication
Neurology / Antiepileptic
Status
Approved
Signal Score
8.2
Glenmark Pharmaceuticals has submitted a supplemental application for Lamotrigine under ANDA090169, currently under standard review.
Company
Impax Labs
Asset
Doxycycline Hyclate
Indication
Infectious Disease / Antibiotic
Status
Approved
Signal Score
8.2
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for a supplement of Doxycycline Hyclate submitted by Impax Labs.
RISING
Asset
MESNA
Indication
Oncology / Supportive Care
Status
Approved
Signal Score
8.2
The FDA has granted an Abbreviated Approval (AP) status for the MESNA ANDA203364 submission from RISING.
Genentech
Asset
VABYSMO
Indication
Ophthalmology / Anti-VEGF
Status
Approved
Signal Score
8.2
The FDA has accepted a supplemental application for VABYSMO (BLA761235) from Genentech.
Micro Labs
Asset
Losartan Potassium
Indication
Cardiovascular / Antihypertensive
Status
Approved
Signal Score
8.2
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Losartan Potassium submitted by Micro Labs.
Company
Alembic
Asset
Duloxetine Hydrochloride
Indication
Neurology / Depression
Status
Approved
Signal Score
8.2
Alembic's application for Duloxetine Hydrochloride has received an Abbreviated Approval (AP) status from the FDA.
Company
Upsher Smith Labs
Asset
Deflazacort
Indication
Immunology / Corticosteroid
Status
Approved
Signal Score
8.2
The FDA has approved a supplemental application for Deflazacort submitted by Upsher Smith Labs.
Aurobindo Pharma
Asset
Lamotrigine
Indication
Neurology / Antiepileptic
Status
Approved
Signal Score
8.2
Aurobindo Pharma's ANDA078956 for Lamotrigine has received an Abbreviated Approval (AP) status from the FDA.
Chartwell RX
Asset
levetiracetam
Indication
Neurology / Antiepileptic
Status
Approved
Signal Score
8.2
The FDA has approved a supplemental application for levetiracetam submitted by Chartwell RX.
THEA PHARMA
Asset
COSOPT PF
Indication
Ophthalmology / Glaucoma
Status
Approved
Signal Score
8.2
The FDA has accepted the supplemental application NDA202667 for COSOPT PF, a glaucoma treatment.
Company
Baxter Healthcare
Asset
Phenylephrine Hydrochloride
Indication
Cardiovascular / Vasopressor
Status
Approved
Signal Score
8.2
The FDA has granted approval for ANDA217032, a new application for Phenylephrine Hydrochloride submitted by Baxter Healthcare.
PHARM ASSOC.
Asset
Ondansetron Hydrochloride
Indication
Oncology / Antiemetic
Status
Approved
Signal Score
8.2
The FDA has received a supplemental application (ANDA078127) for Ondansetron Hydrochloride from PHARM ASSOC.
United Therapeutics
Asset
Tyvaso
Indication
Pulmonary Arterial Hypertension / Prostacyclin Analog
Status
Approved
Signal Score
8.2
The FDA has accepted a supplemental application for Tyvaso, an inhaled formulation of treprostinil.
Signal Score
8.2
Jiangsu Hansoh Pharma has submitted an original application (ANDA216119) for Dapagliflozin, currently under standard review.
Company
Oncology
Asset
HER2-positive solid tumours
Indication
Oncology / HER2-positive solid tumours
Status
Approved
Signal Score
8.4
Enhertu has been recommended for approval by the CHMP for patients with previously treated HER2-positive metastatic solid tumours.
General
Asset
Drug Safety
Indication
General / Drug Safety
Status
Approved
Signal Score
6.8
The FDA has released guidance to enhance the collection of safety data for drugs and biologics used during pregnancy.
Company
Cardiology
Asset
Hypertension
Indication
Cardiology / Hypertension
Status
Approved
Signal Score
8.4
Baxfendy has been approved in the US as the first and only aldosterone synthase inhibitor for adults with hypertension, showing a significant reduction in systolic blood pressure.
Respiratory
Asset
Asthma
Indication
Respiratory / Asthma
Status
Approved
Signal Score
8.4
Breztri has been approved in the US as the first and only triple therapy for asthma in patients aged 12 and older, based on positive Phase III trial results.